Question
|
Answer
|
1. Does your trust treat adult multiple myeloma [MM] ? - if you refer your multiple myeloma patients to another centre, please state which.
|
Yes
|
2. If yes, then how many MM patients, have been treated in the past 6 months with the following;
|
Patient numbers for period 01/12/2018 to 31/5/2019
|
· Bortezomib [Velcade]
|
27
|
· Carfilzomib [Kyprolis]
|
0
|
· Ixazomib [Ninlaro]
|
6
|
· Lenalidomide [Revlimid]
|
16
|
· Daratumumab [Darzalex]
|
Less than 5
|
· Melphalan, prednisolone and thalidomide (known as MPT)
|
Less than 5
|
· Cyclophosphamide, thalidomide and dexamethasone (known as CTD)
|
8
|
· Pomalidomide [Imnovid]
|
9
|
3. If you are able to split by therapy line for question 2, please indicate the number of patients above being treated, 1st line and 2nd line.
|
Information on indication is not collected in the dispensing system and would require a manual search through the patient records. In this instance we would be relying on the exemption under Section 12 of the Freedom of Information Act 2000, as collating and providing this information would require more than 18 hours.
|
4. Does your trust treat adult/paediatric primary immune thrombocytopenia patients [ITP] ? - if you refer your adult/paediatric primary immune thrombocytopenia patients to another centre, please state which.
|
Yes
|
5. If yes, then of the treated adult/paediatric primary immune thrombocytopenia patients, how many are on the following;
|
Patient numbers for period 01/12/2018 to 31/5/2019 but no treatment indication
|
· Eltrombopag [Revolade]
|
Less than 5
|
· Romiplostim [Nplate]
|
0
|
6. At what line of treatment would you currently use a Thrombopoietin Receptor Agonist [TPO] (Eltrombopag [Revolade], Romiplostim [Nplate]) in an immune thrombocytopenia purpura [ITP] patient.
|
|
· 1st
|
|
· 2nd
|
|
· 3rd
|
Eltrombopag
|
· 4th
|
Romiplostim
|
· Unknown
|
|
7. Do you treat patients with a Thrombopoietin Receptor Agonist TPO for the following diseases?
|
|
7a. Chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy
|
No
|
· Eltrombopag [Revolade]
|
|
· Romiplostim [Nplate]
|
|
7b.Acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation
|
|
· Eltrombopag [Revolade]
|
Yes
|
· Romiplostim [Nplate]
|
|
7c. Chemotherapy induced thrombocytopenia (CIT)
|
No
|
· Eltrombopag [Revolade]
|
|
· Romiplostim [Nplate]
|
|
· 7d myelodysplastic syndromes (MDS)
|
|
· Eltrombopag [Revolade]
|
|
· Romiplostim [Nplate]
|
|
8. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?
|
Between Jan 19 and Jun 19 there were 24 patients with a treatment recorded for CLL on the Somerset Cancer Register.
|
9. If possible how many CLL patients treated were new to therapy in the past 3 months?
|
8 patients.
|
10. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
|
Unfortunately we cannot provide this information as these drugs can be used for multiple indications which are not recorded at point of dispensing.
|
· Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR)
|
|
· Bendamustine and rituximab (known as BR)
|
|
· Ibrutinib [Imbruvica]
|
|
· Chlorambucil
|
|
· Venetoclax
|
|
· Obinutuzumab
|
|
· Idelalisib
|
|
· Fludarabine and rituximab (known as FR)
|
|
· High-dose prednisone and rituximab
|
|
· Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)
|
|
· Alemtuzumab (Campath) with rituximab
|
|